Skin Microbiome Startup DermBiont Raises $8M Series A to Treat the Root Cause of Skin Diseases

DermBiont, a clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has closed an $8M Series A. The funding round was led by Zola Global Investors, Toba Capital, and Viking Global Investors. The financing proceeds will be used to fund ongoing clinical trials and